|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT02035501 |
|
Date of registration:
|
02/07/2013 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Treatment of TNNT1-Myopathy With L-Tyrosine.
|
|
Scientific title:
|
Treatment of TNNT1-Myopathy With L-Tyrosine. A Double-blind, Placebo-controlled Crossover Trial. |
|
Date of first enrolment:
|
January 2014 |
|
Target sample size:
|
10 |
|
Recruitment status: |
Enrolling by invitation |
|
URL:
|
http://clinicaltrials.gov/show/NCT02035501 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
|
|
Phase:
|
Phase 2
|
|
|
Countries of recruitment
|
|
Israel
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Male or female patients
- any age with TNNT1-related myopathy
Exclusion Criteria:
- Patients who are non-cooperative or parents/ legal guardians who are unwilling to
sign consent form
Age minimum:
N/A
Age maximum:
20 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Nemaline Myopathy
|
|
Intervention(s)
|
|
Drug: L-Tyrosine
|
|
Drug: Placebo
|
|
Primary Outcome(s)
|
|
1. goal attainment score
[Time Frame: 3 month]
|
|
Secondary ID(s)
|
|
SimonEdvardson1
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|